Selective and specific inhibition of If with ivabradine for the treatment of coronary artery disease or heart failure

Drugs

Volumn 73, Issue 14, 2013, Pages 1569-1586

  Deedwania, Prakash ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BISOPROLOL; CARVEDILOL; DIGOXIN; DIHYDROPYRIDINE; IVABRADINE; MOLSIDOMINE; NICORANDIL; NITRATE; PROPRANOLOL; SILDENAFIL; TRIMETAZIDINE; WARFARIN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; BLOOD FLOW VELOCITY; CARDIAC PATIENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EXERCISE TOLERANCE; FIRST PASS EFFECT; GERIATRIC PATIENT; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE RELAXATION; HEART RATE; HEART VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; ION CURRENT; KIDNEY CLEARANCE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; OXIDATION REDUCTION POTENTIAL; OXYGEN SUPPLY; QUALITY OF LIFE; REVIEW; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; SYSTOLIC HEART FAILURE; VISUAL ANALOG SCALE;

ANIMALS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; HEART FAILURE; HEART RATE; HUMANS;

EID: 84898632006     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0117-0     Document Type: Review

References (76)

1. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44
2. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817-21
3. Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327-34
4. Böhm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010;376(9744):886-94
5. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103(10):1428-33
6. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8(7):369-79
7. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757-65
8. DiFrancesco D. Pacemaker mechanisms in cardiac tissue. Annu Rev Physiol. 1993;55:455-72
9. Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol. 1996;118(4):1051-7
10. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node If channels by ivabradine. J Gen Physiol. 2002;120(1):1-13
11. Canet E, Lerebours G, Vilaine JP. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Ann N Y Acad Sci. 2011;1222:90-9
12. Bucchi A, Tognati A, Milanesi R, et al. Properties of ivabradineinduced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572(Pt 2):335-46
13. Thollon C, Bedut S, Villeneuve N, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150(1):37-46
14. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R&D. 2003;4(2):83-9
15. Manz M, Reuter M, Lauck G, et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149-55
16. Borer JS, Le Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective If current inhibitor. Am J Ther. 2008;15(5):461-73
17. Mangoni E, Fontanaud P, Bouly M, et al. Relationship between If current inhibition by ivabradine and cardiac pacemaker activity [abstract P2301]. Eur Heart J. 2006;27(suppl 1):380
18. Severi S, Fantini M, Charawi LA, et al. An updated computational model of rabbit sinoatrial action potential to investigate the mechanisms of heart rate modulation. J Physiol. 2012;590(Pt 18):4483-99
19. Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817-23
20. Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokineticpharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64(2):192-203
21. Tendera M, Borer JS, Tardif JC. Efficacy of If inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology. 2009;114(2):116-25
22. Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol. 2011;107(6):805-11
23. Tardif J-C, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529-36
24. Lo?pez-Besco?s L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387-96
25. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284(2):H676-82
26. Colin P, Ghaleh B, Monnet X, et al. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs. J Pharmacol Exp Ther. 2004;308(1):236-40
27. Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282(2):H672-9
28. Simon L, Ghaleh B, Puybasset L, et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275(2): 659-66
29. Ceconi C, Cargnoni A, Francolini G, et al. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res. 2009;84(1):72-82
30. Vilaine JP, Bidouard JP, Lesage L, et al. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exerciseinduced myocardial ischemia in pigs. J Cardiovasc Pharmacol. 2003;42(5):688-96
31. Monnet X, Ghaleh B, Colin P, et al. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther. 2001;299(3):1133-9
32. Monnet X, Colin P, Ghaleh B, et al. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004;25(7):579-86
33. Heusch G, Skyschally A, Gres P, et al. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008;29(18):2265-75
34. Dedkov EI, Zheng W, Christensen LP, et al. Preservation of coronary reserve by ivabradine-induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am J Physiol Heart Circ Physiol. 2007;293(1):H590-8
35. Milliez P, Messaoudi S, Nehme J, et al. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol. 2009;296(2):H435-41
36. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109(13): 1674-9
37. Ceconi C, Comini L, Suffredini S, et al. Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2011;300(1): H366-73
38. Suffredini S, Stillitano F, Comini L, et al. Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts f-channel overexpression. Br J Pharmacol. 2012;165(5):1457-66
39. Becher PM, Lindner D, Miteva K, et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension. 2012;59(5):949-57
40. Drouin A, Gendron ME, Thorin E, et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008;154(4):749-57
41. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117(18):2377-87
42. Custodis F, Fries P, Muller A, et al. Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. J Vasc Res. 2012;49(5):432-40
43. Thorin E, Thorin-Trescases N. Vascular endothelial ageing, heartbeat after heartbeat. Cardiovasc Res. 2009;84(1):24-32
44. Servier. Procoralan- Summary of Product Characteristics [online]. Available from URL: http://www. medicines. org. uk/ emc/medicine/17188/SPC/. Accessed 26 Jul 2012
45. Ruzyllo W, Tendera M, Ford I, et al. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67(3):393-405
46. Skalidis EI, Hamilos MI, Chlouverakis G, et al. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis. 2011;215(1):160-5
47. Britten MB, Zeiher AM, Schachinger V. Microvascular dysfunction in angiographically normal or mildly diseased coronary arteries predicts adverse cardiovascular long-term outcome. Coron Artery Dis. 2004;15(5):259-64
48. Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving b-blocker therapy: a 4-month, randomized, placebocontrolled trial. Eur Heart J. 2009;30(5):540-8
49. Amosova E, Andrejev E, Zaderey I, et al. Efficacy of ivabradine in combination with beta-blocker versus uptitration of betablocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25(6):531-7
50. Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101(5):365-73
51. Tardif JC, Ponikowski P, Kahan T. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2012. doi:10. 1016/j. ijcard. 2012. 01. 011
52. Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17(1):96-103
53. Savonitto S, Ardissiono D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) Study. J Am Coll Cardiol. 1996;27(2):311-6
54. Knight CJ, Fox KM. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators. Am J Cardiol. 1998;81(2):133-6
55. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. Coron Artery Dis. 2002;13(8):427-36
56. Koester R, Kaehler J, Meinertz T. Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol. 2011;100(2):121-8
57. Borer JS, Tardif JC. Efficacy of ivabradine, a selective If inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus. Am J Cardiol. 2010;105(1):29-35
58. Köster R, Kaehler J, Meinertz T. REDUCTION Study Group. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J. 2009;158(4): e51-7
59. Fox K, Ford I, Steg PG, et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-16
60. Ferrari R, Ford I, Fox K, et al. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction-baseline characteristics of the study population. Cardiology. 2008;110(4): 271-82
61. Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337-45
62. Ceconi C, Freedman SB, Tardif JC, et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;146(3):408-14
63. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14): 1787-847
64. Swedberg K, Komajda M, Bohm M, et al. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail. 2010;12(1):75-81
65. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study. Lancet. 2010;376(9744):875-85
66. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11-22
67. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938-45
68. Komajda M, Bohm M, Borer J, et al. Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure. Eur J Heart Fail. 2013;15(1):79-84
69. Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813-20
70. Tardif J-C, O'Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32(20):2507-15
71. Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218-24
72. Sarullo FM, Fazio G, Puccio D, et al. Impact of ''off-label'' use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15(4):349-55
73. Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32(19):2395-404
74. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34(29):2263-70
75. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31(2):95-107
76. Institut de Recherches Internationales Servier. Effects of ivabradine in patients with stable coronary artery disease without heart failure. In: ISRCTN register [online] Available from URL: http:// www. controlled-trials. com/ISRCTN61576291 Accessed 14 Mar 2012.